Sign in

    Christopher Lu

    Research Analyst at SVB Leerink

    Christopher Lu is a Research Analyst at SVB Leerink specializing in biopharmaceutical equity research with a focus on clinical-stage companies. He has covered firms such as HOOKIPA Pharma and Pharvaris NV, with records showing active participation in earnings calls and initiating coverage with Outperform ratings. Lu began his analyst career in the early 2020s and has since established himself within SVB Leerink’s healthcare research team, though prior professional experience and additional firm history are not publicly documented. His FINRA registration and securities licenses, as well as notable performance rankings or award recognitions, are not detailed in available sources.

    Christopher Lu's questions to HOOKIPA Pharma (HOOK) leadership

    Christopher Lu's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2020

    Question

    Christopher Lu of SVB Leerink inquired about the upcoming AACR presentation, asking if preliminary efficacy data for the alternating dose regimen would be shared, how to interpret the read-through from immunogenicity to efficacy, and if multiple clinical updates for the alternating regimen were planned.

    Answer

    Igor Matushansky, Chief Medical Officer, clarified that the AACR presentation will focus exclusively on translational data, with clinical efficacy updates reserved for the ASCO conference in June. He explained that based on preclinical data, improved immunogenicity is expected to translate to improved efficacy. Matushansky confirmed that clinical efficacy for both the HB-201 and HB-201/HB-202 programs would be updated at ASCO.

    Ask Fintool Equity Research AI